

22096

Pat. Appl. 10/030,436



IN THE U.S. PATENT AND TRADEMARK OFFICE

Inventor Zoltan GREFF et al  
Patent App. 10/030,436  
Filed 21 March 2002 Conf. No. 6522  
For 2,3-BENZODIAZEPINE DERIVATIVES  
Art Unit 1624 Examiner COLEMAN, B

Hon. Commissioner of Patents  
Box 1450  
Alexandria, VA 22313-1450

## DECLARATION UNDER 37 CFR 1.132

I, Laszlo G. Harsing, a citizen of Hungary, residing at 116 Bokenyfoldi út, 1165 Budapest, Hungary, declare as follows:

THAT I have a number of years of experience in the preparation and testing of pharmaceutically active compounds in the treatment of neurodegenerative disorders;

THAT my full curriculum vitae may be attached thereto;

THAT I am an Applicant in U.S. Patent Application Serial No. 10/030,436 filed 21 March 2002 and directed to 2,3-BENZODIAZEPINE DERIVATIVES;

THAT in order to establish that the present application enables one "skilled in the art" to use the compounds of the Formula (I) to treat Parkinson's disease and multiple sclerosis in mammals, including humans, I have either personally conducted or supervised the carrying out of the following tests:

**BEST AVAILABLE COPY**

## 1 Effects of AMPA antagonists in an animal model of Parkinson's disease

The clinical rating scale of Parkinson's disease consists of several measures of parkinsonian features (tremor, posture, catalepsy, bradykinesia, gait, balance and defense reaction). The rodent model of Parkinson's disease used was a drug-induced monoamine-depletion, which reduces striatal dopamine content by about 95%, and produces a cataleptic effect, which is also a characteristic of human Parkinson's disease (Cooper DR. et al. (1987) L-dopa esters as potential pro-drugs: behavioral activity in experimental models in Parkinson's disease. J. Pharm. Pharmacol. 39, 627-635).

### 1.1. Methods

Male Wistar rats weighing 210-225 g were depleted of brain monoamine by pretreatment with reserpine (5 mg/kg in 2 ml/kg volume, intraperitoneally) 1 hour before the experiment. Then, 1 hour later, 3 dose levels (2.5 mg/kg, 5 mg/kg, 10 mg/kg in 5 ml/kg volume orally for the Compound of Example 27 and 3.75 mg/kg, 7 mg/kg and 15 mg/kg for bromocriptine) of test or reference substance were administered to separate groups of rats and an additional group was treated with vehicle. Each experiment group consisted of 8 rats. Catalepsy was evaluated with a 12 cm long and 10 cm high horizontal bar at every hour for 5 hours. Each rat was tested with respect to its behavior on the bar. The rat gained a "+" score if it maintained the abnormal (postural) position for more than 30 seconds. In case catalepsy was reduced by more than 50% in any of the treated groups compared the reserpine+vehicle treated group, an ED<sub>50</sub> was calculated using the method of Litchfield and Wilcoxon.

22096

### 1.2. Results

According to results presented in Table 1 below, the compound of Example 27 of the present Patent Application reduced reserpine-induced catalepsy with similar efficacy to bromocriptine. The results suggest that compounds of Formula (I) of the present invention can be suitable for the treatment of Parkinson's disease. This suggestion is strengthened by previous publications which clearly demonstrated that non-competitive AMPA receptor antagonists had strong antiparkinsonian effect in a primate model of the disease (Konitsiotis, S. et al. (2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54, 1589-1595).

Table 1

Antiparkinsonian effect of AMPA antagonists as assessed by improvement of reserpine-induced catalepsy in rats

Compound	ED <sub>50</sub> (mg/kg p.o.)
Bromocriptine (reference compound)	3.0
Compound of Example 27	4.4

### 2 Protection against inflammation induced by experimental autoimmune encephalomyelitis (EAE) in rats

Multiple sclerosis is an autoimmune disease of the central nervous system that results in progressive fall of sensory and motor functions due to destruction of the myelin sheath of axons leading to neuronal death. It has been clearly shown that glutamate receptors including AMPA receptors are present in oligodendrocytes and these cells are highly sensitive to glutamate-induced excitotoxicity (Matute, C. et al. (2001) The

link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci. 24, 224-230). Experimental autoimmune encephalomyelitis (EAE) can be induced in laboratory animals by treating them with basic myeloprotein or its fragments carrying the antigen moiety. EAE mimics the basic characteristics of the human disease and can be regarded as an acceptable model of multiple sclerosis (Smith, T et al.: (2000) Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6, 62-66).

## 2.1 Methods

The experiments were performed according to the slightly modified method of Smith and al (Smith, T et al. (2000) Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6, 62-66). Lewis rats (230-270 g, Charles River Hungary) were immunized subcutaneously in the dorsal surface of each hind paw with 50 µl inoculum containing 100 µg of guinea pig myelin basic protein that was emulsified in Freund's complete adjuvant containing 5.5 mg/ml Mycobacterium tuberculosis H37a (Difco). The compounds were administered intraperitoneally twice a day for 7 days starting on the day 10 after immunization. The dose of the compound of Example 28 was 3 mg/kg i.p. twice a day and the dose of the reference compound {(±)-7-acetil-5-(4-aminophenyl)-7,8-dihydro-8-methyl-9H-1,3-methylenedioxy[4,5-h][2,3]benzodiazepine, GYKI53405} was 10 mg/kg i.p. twice a day. On day 17 the rats were anesthetized with sodium pentobarbital at 60 mg/kg i.p. and perfused via the heart with a fixative solution containing 4% paraformaldehyde and 0.5% glutaraldehyde in phosphate-buffered saline. Samples were embedded in paraffin. Transversal sections (6 µm thick) of the lumbar spinal cord and telencephalon were cut and stained with Luxol Fast Blue (LFB).

22096

## 2.2. Results

Key histological features of experimental autoimmune encephalomyelitis were multifocal perivascular inflammation in the medulla and spinal cord, gliosis, demyelination and necrotic or apoptotic degeneration of glial cells or neurons. According to results presented in Table 2 below, compound of Example 28 fully prevented all inflammatory consequences of experimental autoimmune encephalomyelitis in rats. GYKI53405, the reference compound afforded smaller protection under the same experimental conditions. These results clearly suggest that compounds of Formula (I) of the present invention can be suitable in the treatment of multiple sclerosis which possibly is in keeping with observations demonstrating a beneficial effect of non-competitive AMPA antagonists in animal models of multiple sclerosis (Smith, T et al.: (2000) Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6, 62-66).

22096

Table 2

Improvement of histological signs of experimental autoimmune encephalomyelitis by treatment with AMPA receptor antagonists in rats

Histological findings	Control		GYKI53405		Compound of Example 28	
	Mean score	Rate	Mean score	Rate	Mean score	Rate
<b>Medulla oblongata</b>						
multifocal perivascular inflammation in the medulla	2,0	6/6	0,2	1/5	0,0	0/5
gliosis	2,0	5/6	0,2	1/5	0,0	0/5
necrotic/apoptotic cells (glial cells and/or neurons)	0,7	3/6	0,0	0/5	0,0	0/5
<b>Spinal cord</b>						
multifocal perivascular inflammation	2,2	6/6	0,8	2/5	0,0	0/5
demyelination	1,5	6/6	0,8	2/5	0,0	0/5
gliosis	1,8	6/6	0,8	2/5	0,0	0/5
necrotic/apoptotic cells (glial cells and/or neurons)	2,0	6/6	0,4	2/5	0,0	0/5
<b>Nerves</b>						
demyelination	1,8	5/5	0,0	0/3	0,0	0/5
glial destruction	1,8	5/5	0,0	0/3	0,0	0/5

THAT based upon the experimental data presented above, I conclude the following:

The compounds of the Formula (I) of the present invention are non-competitive AMPA antagonists. Experimental results obtained from animal model experiments indicate that compounds of the present invention possess strong neuroprotective effect, which is useful in the treatment of conditions and diseases of the central nervous system. Besides their effect in animal models of epilepsy, stroke, amyotrophic lateral sclerosis and cystic periventricular leukomalacia, the compounds according to the present invention demonstrate activity in animal models of Parkinson's disease and multiple

22096

sclerosis as well. All these activity of the compounds of Formula (I) of the present invention are believed to be resulting from AMPA receptor antagonism. The mechanism whereby AMPA receptor antagonists prevent neuronal cell death in disorders of very different etiology is the inhibition of glutamate-induced excitotoxicity, which is a major mechanism leading to apoptosis and necrosis of nerve cells. The experimental data presented hereinabove provide support for the establishment of utility of the compounds according to the present invention in neurodegenerative disorders. In summary, the compounds of the Formula (I) according to the present invention have suprisingly advantageous pharmacokinetic and metabolic properties which result in a preferable pharmacological and toxicological profile. THAT I am aware of no information inconsistent with that presented above or which would lead one to a contrary conclusion;

and

I further declare that all statements made herein of my own are true and that all statements made on information and belief are believed to be true; and further

THAT these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issues thereon.

Dated: \_\_\_\_\_

Signed: \_\_\_\_\_

Laszlo G Harsing, MD, PhD, DSC

2004-NOV-30 12:55

HONNAN:EGIS\_Rt.IPARJOG

+36-1-2655763

T-109 0 027/049 F-176

## CURRICULUM VITAE

Name: Dr. Laszlo Gabor Harsing

Date and Place of Birth: September 9, 1947, Budapest, Hungary

Citizenship: Hungarian

### Marital Status

Married, Elizabeth Veinperl-Harsing  
Pharmacist

### Present Employment

Vice Director, Head of Division  
Division of Preclinical Research  
EGIS Pharmaceuticals Ltd

### Education

1966: Graduated from secondary school

1972: Medical degree obtained with qualification of "Summa cum Laude" at the Semmelweis Medical School, Budapest

1984: Ph.D. degree obtained in neuropharmacology  
Thesis: Regulation of Cholinergic Neurotransmission in the Striatum  
Hungarian Academy of Sciences, Budapest

1992: Doctor of Sciences (D.Sc.) degree obtained in neuropharmacology  
Thesis: The Role of Heterogenous Alpha-2 Adrenoceptors in the Regulation of Noradrenergic Neurotransmission  
Hungarian Academy of Sciences, Budapest

1994: Lecturer in Pharmacology, degree obtained at the Department of Pharmacology, Semmelweis Medical School, Budapest

### Employment in Hungary

1968-1972: Teacher in Physiology, Department of Physiology, Semmelweis Medical School, Budapest

1972-1981: Assistant Professor of Pharmacology, Department of Pharmacology, Semmelweis Medical School, Budapest



2004-NOV-30 12:55

HONNAN:EGIS Rt. IPARJOG

+36-1-2655763

T-109 0.028/049 F-176

1981-1986: Research Fellow and Senior Research Fellow, Department of Pharmacology,  
Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest

1986-1995: Associate Professor of Pharmacology, Department of Pharmacology  
Postgraduate Medical School, Budapest

1992-2000: Head, Department of Neurobiochemistry  
Vice Director of Biological Research  
Institute for Drug Research, Ltd., Budapest

2000-at present: Vice Director and Head  
Division of Preclinical Research  
EGIS Pharmaceuticals Ltd

#### Employment in the United States of America

1980-1981: Visiting Scientist, Fogarty International Fellowship, Laboratory of Preclinical  
Pharmacology, National Institute of Mental Health, Washington,  
D. C., USA, Head: Dr. Erminio Costa, 20 months

1984-1985: Visiting Fellow, Department of Anesthesiology, Albert Einstein College of  
Medicine, New York, NY, USA, Head: Dr. Derick D. Duncalf, 13 months

1989-1992: Research Scientist, Center for Neurochemistry, The Nathan S. Kline Institute  
for Psychiatric Research, Rockland Psychiatric Center, Orangeburg, NY, USA, Head:  
Dr. Abel Lajtha, 36 months

1995-1996: Visiting Research Scientist, Fogarty International Fellowship, Department of  
Neuroscience, University of Pittsburgh, Pittsburgh, PA, USA, Head: Dr. Michael J.  
Zigmond, 20 months

#### Short-Term Fellowships

1975: Department of Pharmacology, 1st Medical University, Moscow, USSR

1976: Institute of Physiology, Bulgarian Academy of Sciences, Sofia, Bulgaria

1977: Institute of Pharmacology, Polish Academy of Sciences, Cracow, Poland

1982: National Institute of Mental Health, Washington, D.C., USA

1987 Department of Pharmacology, University of Geneva, Geneva, Switzerland

1988 Universidad Central de Venezuela, Caracas, Venezuela

1993 Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA

2004-NOV-30 12:56

HONNAN:EGIS Rt. IPARJOG

+36-1-2655763

T-109 0.029/049 F-176

1998 Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA

#### Research Activity

Publications in journals: 93

Chapters published in textbooks: 37

Abstracts appeared in journals: 26

Abstracts presented in scientific meetings: 95

Number of citation: 1170, January 2003

Cumulative impact factor of publications: 206.470, January, 2003

#### Teaching Experience

1970-1972: Teaching of physiology for medical students

1972-at present: Teaching of pharmacology for medical students and in postgraduate courses

#### Research Interest

Pharmacology, Neuropharmacology, Neurochemistry, Neurotransmitter release and interactions, Pharmacology of Transporters

#### Experimental Procedures Employed

Brain slice techniques, Isolated organs, Microdialysis and HPLC analysis, Measurement of radiolabeled and endogenous neurotransmitter release

#### Membership

Society for Neuroscience, USA

British Pharmacological Society

European Society for Neurochemistry

Hungarian Pharmacological Society

Hungarian Physiological Society

#### Journal Editorial Advisory Board, Member at

Neurochemical Research

Neurochemistry International

2004-NOV-30 12:56

HONNAN:EGIS Rt.1PARJOG.

+36-1-2655763

T-108 0.030/048 F-176

Honour  
Bela Issekutz Lecture and Medal  
Budapest, 2001

Reference  
Dr. Henry Sershen, Center for Neurochemistry, The Nathan Kline Institute for Psychiatric  
Research, Orangeburgh, NY, USA. Tel.: 1-914-398-5530

Dr. Laszlo G. Harsing, Jr.

## LIST OF PUBLICATIONS

### 1. RESEARCH ARTICLES

1. Harsing, L., Harsing, L., Jr., Bartha, J.: Új szempontok az intrarenális haemodynamikában. *Orvostudomány*, 1972, 23, 295-301.
2. Kover, G., Harsing, L. G., Harsing, L.: Effect of elevated renal venous pressure on intrarenal haemodynamics. *Acta Physiol. Hung.*, 1974, 45, 173-180.
3. Knoll, J., Makleit, S., Friedmann, T., Harsing, L. G., Jr., Hadhazy, P.: Circulatory, respiratory and antitussive effects of azidomorphine and related substances. *Arch. Internat. Pharmacodyn.*, 1974, 210, 241-249.
4. Knoll, J., Makleit, S., Friedmann, T., Harsing, L. G., Hadhazy, P.: Az azidomorfin és származékainak hatása a keringésre, légzésre és köhögésre. *Orvostudomány*, 1975, 26, 89-95.
5. Harsing, L. G., Jr., Bartha, J., Harsing, L.: Effect of carotid occlusion on intrarenal haemodynamics. *Acta Medica Hung.* 1976, 33, 371-378.
6. Knoll, J., Harsing, L. G., Friedmann, T.: A 3-éter-6-azidomorfinok farmakológiája. Az azidoetilmorfin egy új köhögéscsillapító szelektálása. *Orvostudomány*, 1976, 27, 263-284.
7. Knoll, J., Harsing, L. G., Jr., Friedmann, T.: Azidoethylmorphine, a new potent non-narcotic oral antitussive. *Acta Physiol. Hung.*, 1977, 50, 341-356.
8. Vizi, E. S., Ronai, A. Z., Harsing, L. G., Jr., Knoll, J.: Inhibitory effect of dopamine on acetylcholine release from caudate nucleus. *Pol. J. Pharmacol. Pharmac.*, 1977, 29, 201-211.
9. Vizi, E. S., Harsing, L. G., Jr., Knoll, J.: Presynaptic inhibition leading to disinhibition of acetylcholine release from interneurons of the caudate nucleus: effect of dopamine, beta-endorphin and D-Ala2-Pro5-enkephalinamide. *Neuroscience*, 1977, 2, 953-961.
10. Harsing, L. G., Jr., Vizi, E. S., Knoll, J.: Increase by enkephalin of acetylcholine release from striatal slices of the rat. *Pol. J. Pharmacol. Pharmac.*, 1978, 30, 387-395.
11. Harsing, L. G., Jr., Magyar, K., Tekes, K., Vizi, E. S., Knoll, J.: Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition. *Pol. J. Pharmacol. Pharmac.*, 1979, 31, 297-307.
12. Harsing, L. G., Jr., Illes, P., Furst, S., Vizi, E. S., Knoll, J.: The effect of prostaglandin E1 on acetylcholine release from cat brain. *Acta Physiol. Hung.*, 1979, 54, 177-185.
13. Magyar, K., Harsing, L. G., Jr., Tekes, K., Knoll, J.: The role of 1metabolic factors in the interaction between opiates and homopyrimidazoles in the central nervous system. *Arch. Toxicol.*, 1980, 4, 376-379.
14. Vizi, E. S., Harsing, L. G., Jr., Zsilla, G.: Evidence of the modulatory role of serotonin in acetylcholine release from striatal interneurons. *Brain Res.*, 1981, 212, 89-99.
15. Harsing, L. G., Jr., Yang, H.-Y. T., Govoni, S., Costa, E.: Elevation of

met5-enkephalin and beta-endorphin hypothalamic content in rats receiving anorectic drugs: differences between d-fenfluramine and d-amphetamine. *Neuropharmacology*, 1982, 21, 141-145.

16. Harsing, L. G., Jr., Yang, H.-Y. T., Costa, E.: Evidence for a gamma-aminobutyric acid (GABA) mediation in the benzodiazepine inhibition of the release of met5-enkephalin elicited by depolarization. *J. Pharm. Exp. Ther.*, 1982, 220, 616-620.

17. Harsing, L. G., Jr., Yang, H.-Y. T., Costa, E.: Accumulation of hypothalamic endorphins after repeated injections of anorectics which release serotonin. *J. Pharm. Exp. Ther.*, 1982, 223, 689-694.

18. Ronai, A. Z., Harsing, L. G., Jr., Berzetei, I. P., Bajusz, S., Vizi, E. S.: Met5-enkephalin-arg-phe acts on vascular opiate receptors. *Eur. J. Pharmacol.*, 1982, 79, 337-338.

19. Hársing, L. G. Jr., Vizi, E. S.: A katelepszia és a striatális acetilkolin felszabadulás összefüggése. *Orvostudomány*, 1982, 33, 99-112.

20. Tarczy, M., Harsing, L. G., Jr., Csanda, E., Vizi, E. S.: Untersuchung des Zusammenhangs zwischen der motorischen Leistung und dem Plasma-L-Dopa-Spiegel bei Parkinson Kranken mit "on-off"-Phänomen. *Neuropsychiatr.*, 1983, 2, 229-234.

21. Harsing, L. G., Jr., Ronai, A. Z., Somogyi, G. T., Umezawa, H., Bajusz, S., Vizi, E. S.: Met5-enkephalin-Arg6-Phe7 inhibition of noradrenaline and acetylcholine release from peripheral organs. *J. Auton. Pharmacol.*, 1984, 4, 33-43.

22. Ronai, A. Z., Serfozo, P., Harsing, L. G., Jr., Vizi, E. S.: The conversion of met-enkephalin-Arg6-Phe7 to met-enkephalin in rabbit ear artery. *Life Sciences*, 1984, 33, 101-104.

23. Varga, G., Papp, M., Harsing, L. G. Jr., Toth, I., Gaal, G., Somogyi, G. T., Vizi, E. S.: Study of neuroeffector transmission of hepatic and pancreaticoduodenal isolated arteries of the dog. *Gastroenterology*, 1984, 87, 1056-1063.

24. Harsing, L. G., Jr., Vizi, E. S.: Release of endogenous dopamine from the rat striatum: effect of clorgyline and (-)-deprenyl. *Br. J. Pharmacol.*, 1984, 83, 741-749.

25. Harsing, L. G., Jr., Vizi, E. S.: Evidence for multiple dopamine receptors involved in the modulation of acetylcholine release in the striatum. *Pol. J. Pharmacol. Pharmac.*, 1985, 37, 383-396.

26. Kanyicska, B., Simonyi, A., Harsing, L. G., Jr., Vizi, E. S., Fekete, M. I. K., Stark, E.: Catalepsy, hypermotility and increase of striatal acetylcholine release induced by opioids (morphine and met-enkephalin) as affected by prolonged hydrocortisone and ACTH treatment. *Pol. J. Pharmacol. Pharmac.*, 1985, 37, 383-396.

27. Vizi, E. S., Harsing, L. G., Jr., Duncalf, D., Nagashima, H., Foldes, F.: A simple and sensitive method of acetylcholine identification and assay. *J. Pharmacological Methods*, 1985, 13, 201-211.

28. Potter, P. E., Harsing, L. G., Jr., Kakucska, I., Gaal, G., Vizi, E. S.: Peripheral and central actions of AF64A (ethylcholine mustard aziridinium ion) on acetylcholine release in vitro: comparison with hemicholinium. *Neurochem. Internat.*, 1985, 7, 1047-1053.

29. Ludvig, N., Harsing, L. G., Jr., Hideg, J., Vizi, E. S.: Reduced cyclic-AMP responsiveness in the colliculus inferior of audiogenic seizure-prone rats. *Biochem. Pharmacol.*, 1985, 34, 2042-2044.

30. Vizi, E. S., Harsing, L. G., Jr., Zimanyi, I., Gaal, G.: Release and turnover of Inoradrenaline in isolated median eminence: lack of negative feedback modulation.

Neuroscience, 1985, 16, 907-916.

31. Kapocsi, J., Somogyi, G. T., Harsing, L. G., Jr., Vizi, E. S.: Prazosin preszinaptikus hatása a periférián. Neurokémiai bizonyítékok. Kísérletes Orvostudomány, 1985, 37, 260-268.

32. Vizi, E. S., Somogyi, G. T., Harsing, L. G., Jr., Zimanyi, I.: External Ca-independent release of norepinephrine by sympathomimetics and its role in negative feedback modulation. Proc. Nat. Acad. Sci. U. S. A., 1985, 82, 8775-8780.

33. Potter, P. E., Harsing, L. G., Jr., Kakucska, I., Gaal, G., Vizi, E. S.: Selective impairment of acetylcholine release content in the central nervous system following intracerebroventricular administration of AF64A in the rat. Neurochem. Internat., 1986, 8, 199-206.

34. Harsing, L. G., Jr., Nagashima, H., Vizi, E. S., Duncalf, D.: Electrochemical and chromatographic properties of histamine derivatizes with o-phthalaldehyde and 2-mercaptoethanol. J. Chromatogr., 1986, 383, 19-26.

35. Harsing, L. G., Jr., Nagashima, H., Duncalf, D., Vizi, E. S., Goldiner, P. L.: Determination of human plasma histamine levels by high performance liquid chromatography/electrochemistry after derivatization with o-phthalaldehyde and 2-mercaptoethanol. Clinical Chemistry, 1986, 32, 1823-1827.

36. Vizi, E. S., Somogyi, G. T., Harsing, L. G., Zimanyi, I.: Release of 3H-noradrenaline by alpha1-adrenoreceptor agonists. Neurochemical Research, 1986, 11, 71-84.

37. Vizi, E. S., Harsing, L. G., Jr., Gaal, J., Kapocsi, J., Bernath, S., Somogyi, G. T.: CH-38083 a selective, potent antagonist of alpha2-adrenoreceptors. J. Pharm. Exp. Ther., 1986, 238, 701-706.

38. Kobayashi, O., Nagashima, H., Duncalf, D., Chaudhry, I. A., Harsing, L. G., Jr., Foldes, F. F., Goldiner, P. L., Vizi, E. S.: Direct evidence that pancuronium and gallamine enhance the release of norepinephrine from the atrial sympathetic nerve by inhibiting prejunctional muscarinic receptors. J. Auton. Nerv. Syst., 1987, 18, 55-60.

39. Sugimori, T., Nagashima, H., Vizi, E. S., Harsing, L. G., Jr., Lalezari, I., Duncalf, D., Goldiner, P. L., Foldes, F. F.: Effect of mono- and diaminepyridines of 3H-norepinephrine release from isolated guinea pig atrium. Neuropharmacology, 1987, 26, 621-626.

40. Kapocsi, J., Somogyi, G. T., Ludvig, N., Serfozo, P., Harsing, L. G., Jr., Woods, R. J., Vizi, E. S.: Neurochemical evidence for two types of presynaptic alpha-2 adrenoceptors. Neurochemical Research, 1987, 12, 141-147.

41. Vizi, E. S., Toth, I., Harsing, L. G., Jr., Szabo, L., Somogyi, G. T., Szantay, Cs.: Berbanes, a new class of alpha2-adrenoceptor antagonists. J. Med. Chem., 1987, 30, 1355-1359.

42. Harsing, L. G., Jr., Lonart, G., Vizi, E. S.: Berbanes: Search for novel alpha-2 adrenoceptor antagonists. Pol. J. Pharmacol. Pharmac., 1988, 40, 697-708.

43. Harsing, L. G., Jr., Vizi, E. S.: Excitatory amino acids (glutamate and aspartate) in the rat brain: measurement with liquid chromatography coupled with electrochemical detection. Pharm. Res. Comm., 1988, 20, 151-152.

44. Lonart, G., Harsing, L. G., Jr., Vizi, E. S.: Pharmacological evidence for two types of presynaptic alpha-2 adrenoceptors. Pharm. Res. Comm., 1988, 20, 135-136.

45. Foldes, F. F., Kobayashi, O., Kinjo, M., Harsing, L. G., Nagashima, H., Duncalf, D., Goldiner, P. L., Vizi, E. S.: Presynaptic effect of muscle relaxants on the release of

3H-norepinephrine controlled by endogenous acetylcholine in guinea pig atrium. *J. Neural Transmission*, 1989, 76, 169-180.

46. Harsing, L. G., Jr., Lajtha, A., Vizi, E. S.: An HPLC/electrochemical assay of glutamatergic neurotransmission in the rat brain. *Biomedical Chromatography*, 1989, 3, 183-185.

47. Lonart, G., Harsing, L. G., Jr., Folly, G., Vizi, E. S.: Failure of selective antagonists (CH-38083 and idazoxan) to distinguish between prejunctional and postjunctional alpha-2 adrenoceptors. *J. Auton. Pharm.*, 1989, 9, 149-158.

48. Harsing, L. G., Jr., Kapocsi, J., Vizi, E. S.: Possible role of alpha-2 and alpha-1 adrenoceptors in the experimentally induced depression of the central nervous system. *Pharmacology Biochemistry and Behavior*, 1989, 32, 927-932.

49. Zelles, T., Harsing, L. G., Vizi, E. S.: Characterization of neuronal cholecystokinin receptor by L-364,718 in Auerbach's plexus. *Eur. J. Pharmacol.*, 1990, 178, 101-104.

50. Vizi, E. S., Kapocsi, J., Harsing, L. G., Jr., Del Tacca, M.: Heterogeneity of presynaptic alpha-2 adrenoceptors. *Acta Physiol. Hung.*, 1990, 75, 297-298.

51. Gyarmati, S., Harsing, L. G., Jr., Tekes, K., Knoll, J.: Repeated administration of (-)-deprenyl leaves the mesolimbic dopaminergic activity unchanged. *Acta Physiol. Hung.*, 1990, 75, 133-134.

52. Harsing, L. G., Jr., Vizi, E. S.: Evidence that two stereochemically different alpha-2 adrenoceptors modulate norepinephrine release in rat cerebral cortex. *J. Pharmacol. Exp. Ther.*, 1991, 256, 44-49.

53. Harsing, L. G., Jr., Vizi, E. S.: Alpha-2 adrenoceptors are not involved in the regulation of striatal glutamate release: comparison to dopaminergic inhibition. *J. Neurosci. Res.*, 1991, 28, 376-381.

54. Kiem, D. T., Bartha, L., Harsing, L. G., Jr., Makara, G. B.: Reevaluation of the role of alpha-2 adrenoceptors in morphine-stimulated release of growth hormone. *Neuroendocrinology*, 1991, 53, 516-522.

55. Sershen, H., Hashim, A., Harsing, L., Lajtha, A.: Chronic nicotine induced changes in dopaminergic system: effect on behavioral response to dopamine agonist. *Pharm. Biochem. Behav.*, 1991, 39, 545-547.

56. Sershen, H., Harsing, L. G., Jr., Banay-Schwartz, M., Toth, E., Hashim, A., Ramacci, M. T., Lajtha, A.: Effect of acetyl-L-carnitine on the dopaminergic system in aging brain. *J. Neurosci. Res.*, 1991, 30, 555-559.

57. Harsing, L. G., Jr., Vizi, E. S.: Different sites of action for alpha-2 adrenoceptor antagonists in modulation of noradrenaline release and contraction response in the vas deferens of the rat. *J. Pharm. Pharmacol.*, 1992, 44, 231-234.

58. Harsing, L. G., Jr., Sershen, H., Lajtha, A.: N-type  $Ca^{2+}$  channels are involved in the dopamine releasing effect of nicotine. *Neurochemical Research*, 1992, 17, 729-734.

59. Sershen, H., Hashim, A., Harsing, L., Lajtha, A.: Ibogaine antagonizes cocaine-induced locomotor stimulation in mice. *Life Sci.*, 1992, 50, 1079-1086.

60. Harsing, L. G., Jr., Sershen, H., Lajtha, A.: Dopamine efflux from striatum after chronic nicotine: evidence for autoreceptor desensitization. *J. Neurochem.*, 1992, 59, 48-54.

61. Harsing, L. G., Jr., Sershen, H., Toth, E., Hashim, A., Ramacci, M. T., Lajtha, A.: Acetyl-L-carnitine releases dopamine in rat corpus striatum: an in vivo microdialysis study. *Eur. J. Pharmacol.* 1992, 218, 117-121.

2004-NOV-30 12:57 HONNAN:EGIS Rt. PARJOG.

+36-1-2655763

T-100 0.035/040 F-176

62. Sershen, H., Harsing, L. G., Jr., Hashim, A., Lajtha, A.: Ibogaine reduces amphetamine-induced locomotor stimulation in C57BL/6By mice, but stimulates locomotor activity in rats. *Life Sci.*, 1992, 51, 1003-1011.

63. Toth, E., Harsing, L. G., Jr., Sershen, H., Ramacci, M. T., Lajtha, A.: Effect of acetyl-L-carnitine on extracellular amino acid levels in vivo in rat brain regions. *Neurochemical Research*, 1993, 18, 573-578.

64. Timar, J., Gyarmati, Zs., Tekes, K., Harsing, L. G., Knoll, J.: Further proof that (-)deprenyl fails to facilitate mesolimbic dopaminergic activity. *Pharm. Biochem. Behav.*, 1993, 46, 709-714.

65. Harsing, L. G., Jr., Sershen, H., Lajtha, A.: Evidence that ibogaine releases dopamine from the cytoplasmic pool. *J. Neural Transm.*, 1994, 96, 215-225.

66. GYKI-46903. *Drugs of the Future*, 1993, 18, 421-423.

67. Solyom, S., Abraham, G., Szollosy, M., Pallagi, I., Czuzdi, E., Ling, I., Vitalis, B., Horvath, K., Horvath, E. J., Harsing, L. G., Jr., Kajtar, J.: Intramolecular cyclization with oxocarbenium ion. Synthesis of 1-azabicyclo[3.3.1]nonene and [3.2.1]octene derivatives. *Heterocycles*, 1995, 41, 1139-1168.

68. Bagdy, E. and Harsing, L. G., Jr. The role of various calcium and potassium channels in the regulation of somatodendritic serotonin release. *Neurochemical Research*, 1995, 20, 1409-1415.

69. Vitalis, B., Bakonyi, A., Csillik-Perczel, V., Horvath, E., Horvath, K., Mate, I., Szekely, J. I., Yemane, T., Abraham, G., Solyom, S., Harsing, L. G., Jr.: The pharmacology of GYKI-46 903, a new cognition enhancer. *CNS Drug Reviews*, 1995, 1, 129-148.

70. Csillik-Perczel, V., Bakonyi, A., Horvath, E., Solyom, S., Szekely, J. I., Vitalis, B., Yemane, T., Harsing, L. G., Jr.: GYKI-46 903, a noncompetitive antagonist for 5-HT<sub>3</sub> receptors. *Pharmacol. Toxicol.*, 1996, 79, 32-39.

71. Harsing, L. G., Jr., Zigmond, M. J.: Dopaminergic inhibition of striatal GABA release after 6-hydroxydopamine. *Brain Research*, 1996, 738, 142-145.

72. Harsing, L. G., Jr., Zigmond, M. J.: Influence of dopamine on GABA release in striatum: evidence for D1-D2 interactions and non-synaptic influences. *Neuroscience*, 1997, 77, 419-429.

73. Bagdy, E., Solyom, S., Harsing, L. G., Jr.: Feedback stimulation of somatodendritic serotonin release: a 5-HT<sub>3</sub> receptor-mediated effect in the raphe nuclei of the rat. *Brain Research Bulletin*, 1998, 45, 203-208.

74. Harsing, L. G., Jr., Zigmond, M. J.: Postsynaptic integration of cholinergic and dopaminergic signals on medium size GABAergic projection neurons in the neostriatum. *Brain Research Bulletin*, 1998, 45, 607-613.

75. Matyus, P. with Harsing, L. G., Jr., Tapfer, M., Tilahun Yemane: GYKI-16 084. *Drugs of the Future*, 1999, 24, 1072-1077 and 2000, 25, 230.

76. Harsing, L. G., Jr., Csillik-Perczel, V., Ling, I., Solyom, S.: Negative allosteric modulators of AMPA-preferring receptors inhibit [<sup>3</sup>H]GABA release in rat striatum. *Neurochemistry International*, 2000, 37, 33-45.

77. Gartside, S. E., Hajos-Korcsok, E., Bagdy, E., Harsing, L. G., Jr., Sharp, T., Hajos, M.: Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurones. *Neuroscience*, 2000, 98, 295-300.

78. Abraham, G., Solyom, S., Czuzdi, E., Berzsenyi, P., Ling, I., Tarnawa, I., Hamori, T., Pallagi, I., Horvath, K., Andrasi, F., Kapus, G., Harsing, L. G., Jr., Kiralyn I., Pathy, M.,



Horvath, G., Kiraly, I.: New non competitive AMPA antagonists. *Biorg. Med. Chem.* 2000, 8, 2127-2143.

79. Bagdy, E., Kiraly, I., Harsing, L. G., Jr.: Reciprocal innervation between serotonergic and GABAergic neurons in raphe nuclei of the rat. *Neurochem. Res.*, 2000, 11, 1465-1473.

80. Vitalis, B., Sebestyen, L., Sike, M., Solyom, S., Harsing, L. G., Jr.: Binding characteristics of GYKI-46 903, a noncompetitive ligand at 5-HT<sub>3</sub> receptors. *Pharmacol. Res.*, 2001, 43, 291-299.

81. Harsing, L. G., Jr., Solyom, S., Salamon, C.: The role of glycine<sub>B</sub> binding site and glycine transporter (GlyT<sub>1</sub>) in the regulation of [<sup>3</sup>H]GABA and [<sup>3</sup>H]glycine release in the rat brain. *Neurochem. Res.*, 2001, 26, 915-923.

82. Harsing, L. G., Jr., Juranyi, Zs.: Regulation of 5-HT release from raphe nuclei by different 5-HT receptors. *Neuropsychopharmacologia Hungarica*, 2002, 4, 138-146.

83. Leveleki, C., Kompagne, H., Gacsalyi, I., Barkoczy, J., Schmidt, E., Pallagi, K., Harsing, L. G., Levay, G.: Új atipusos antipszichotikumok anxiolitikus hatással. *Neuropsychopharmacologia Hungarica*, 2002, 4, 147-153.

84. Spedding M., Neau, I., Harsing, L.: Brain plasticity and pathology-Evidence for morphological changes affecting brain activation in psychiatric disease: sites of action for potential therapy. *Current Opinion in Pharmacology*, 2003, 3, 1-8.

85. Harsing, L.G., Jr., Gacsalyi, I., Schmidt, E., Szabo, G., Sziray, N., Sebban, C., Tesolin-Decros, B., Matyus, P., Spedding, M., Matyus, P., Levay, G.: The glycine transporter 1 inhibitor NFPS and Org 24461: a pharmacological study. *Pharm. Biochem. Behav.*, 2003, 74, 811-825.

86. Juranyi, Zs., Harsing, L. G., Jr., Zigmond, M. J.: [<sup>3</sup>H]Dopamine release in striatum in response to cortical stimulation in a corticostriatal slice preparation. *J. Neurosci. Methods*, 2003, 126, 57-67.

87. Kapus, G., Kertesz S., Gigler, G., Simo, A., Vegh, M., Barkoczy, J., Harsing, L. G., Jr., Szabo, G., Levay, G.: Comparison of the AMPA antagonist action of new 2,3-benzodiazepines in vitro and their neuroprotective effects in vivo. *Pharm Res.*, 2004, 21, 317-323.

88. Harsing, L. G., Prauda, I., Barkoczy, J., Matyus, P. Juranyi, Zs.: 5-HT<sub>7</sub> heteroreceptor-mediated inhibition of [<sup>3</sup>H]serotonin release in raphe nuclei slices of the rat: evidence for a serotonergic-glutamatergic interaction. *Neurochem. Res.*, 2004, 29, 1479-1489.

89. Matucz, E., Moricz, K., Gigler, G., Simo, A., Barkoczy, J., Levay, Gy., Harsing, L. G., Jr., Szenasi, G.: Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia. *Brain Res.*, 2004, 1019, 210-216.

90. Juranyi, Z., Sziray, N., Levay, G., Harsing, L. G., Jr.: AMPA receptor blockade potentiates the stimulatory effect of L-dopa on dopamine release in dopamine-deficient corticostriatal slice preparation. *Critical Reviews in Neurobiology*, 2004, 16, 129-139.

91. Szenasi, G., Harsing, L. G., Jr.: Pharmacology and prospective therapeutic usefulness of negative allosteric modulators of AMPA receptors. *Drug Discovery Today: Therapeutic Strategies*. 2004, 1, 69-76.

92. Gressens, P., Spedding, M., Villa, P., Medja, F., Williamson, T., Kertesz S., Levay, G., Gigler, G., Szenasi, G., Barkoczy, J., Harsing, L. G., Jr.: The effects of novel

AMPA antagonists in models of neurodegeneration. *Eur. J. Pharmacol.*, accepted for publication.

93. Harsing, L. G., Jr.: Neurochemical transmission in raphe nuclei. *Brain Res. Bulletin*, 2005, submitted.

## 2. CHAPTERS IN TEXTBOOKS

1. Harsing, L. G., Jr., Friedmann, T. Magyar, K., Knoll, J.: The effect of azidoethylmorphine and related substances on cough and respiration. In: *Symposium on Analgesics*, eds.: Knoll, J., Vizi, E. S., Akadémiai Kiadó, Budapest, 1976, pp 61-65.

2. Friedmann, T., Harsing, L. G., Jr., Knoll, J.: The antitussive effects of azidomorphine and 14-hydroxy-azidomorphine. In: *Symposium on Analgesics*, Eds.: Knoll, J., Vizi, E. S., Akadémiai Kiadó, Budapest, 1976, pp 61-65.

3. Vizi, E. S., Harsing, L. G., Jr.: Presynaptic inhibitory effect of noradrenaline and dopamine in the central nervous system and the role of membrane ATPase. In: *Presynaptic receptors*, Eds.: Langer, S. Z., Starke, K., Dubocovich, M. L., Pergamon Press, Oxford, 1978, pp 151-157.

4. Vizi, E. S., Ronai, A. Z., Harsing, L. G., Jr., Knoll, J.: Presynaptic modulation by norepinephrine and dopamine of acetylcholine release in the peripheral and central nervous system. In: *Cholinergic mechanisms and psychopharmacology*. Ed.: Jenden, D. J., Plenum Press, New York, 1978, pp 587-603.

5. Harsing, L. G., Jr., Vizi, E. S.: Different sensitivity of pre- and postsynaptic dopamine receptors in the rat striatum. In: *Modulation of neurochemical transmission*, Ed.: Vizi, E. S., Pergamon Press-Akadémiai Kiadó, Budapest, 1980, pp 181-188.

6. Vizi, E. S., Harsing, L. G., Jr.: Difference in sensitivity of opiate receptors in the striatum to beta-endorphin and enkephalins: evidence that catalepsy is related to enhanced acetylcholine release from cholinergic interneurons. In: *Aminergic and peptidergic receptors*, Eds.: Vizi, E. S., Wollema, M., Pergamon Press-Akadémiai Kiadó, Budapest, 1980, pp 85-94.

7. Tekes, K., Harsing, L. G., Jr., Magyar, K., Knoll, J.: The role of metabolic factors in the interaction between opiates and homopyrimidazoles in the central nervous system. In: *Opiate receptors and the neurochemical correlates of pain*, Ed.: Furst, S., Pergamon Press-Akadémiai Kiadó, Budapest, 1980, pp 201-205.

8. Harsing, L. G., Jr., Tekes, K., Magyar, K., Vizi, E. S., Knoll, J.: Deprenyl inhibits dopamine uptake in the rat striatum in vivo. In: *Monoamine oxidases and their selective inhibition*. Ed.: Magyar, K., Pergamon Press-Akadémiai Kiadó, Budapest, 1980, pp 45-56.

9. Harsing, L. G., Jr., Vizi, E. S.: Sensitivity of opiate receptors in withdrawal syndrome. In: *Aminergic and peptidergic receptors*, Eds.: Vizi, E. S., Wollema, M., Pergamon Press-Akadémiai Kiadó, Budapest, 1980, pp 95-113.

10. Yang, H.-Y. T., Harsing, L. G., Jr., Majane, E. M., Costa, E.: Possible role of dipeptidyl carboxypeptidase in the metabolism of met5-enkephalin and met5-enkephalin-Arg6-Phe7. In: *Regulatory peptides: from the molecular biology to function*. Eds.: Costa, E., Trabucchi, M., Raven Press, New York, 1982, pp 251-260.

11. Harsing, L. G., Jr., Yang, H.-Y. T.: Serotonergic regulation of hypothalamic met5-enkephalin content. In: *Dynamics of neurotransmitter function*, Ed. Hanin, I., Raven Press, New York, 1984, pp 169-176.

2004-NOV-30 12:58

HONNAN:EGIS Rt. IPARJOG

+36-1-2655763

T-108 0.038/048 F-176

12. Vizi, E. S., Harsing, L. G., Jr., Ronai, A. Z.: Peptides as transmitters/modulators. In: Biomedical significance of peptide research, Eds.: Antoni, F., Laszlo, F. A., Akadémiai Kiadó, Budapest, 1984, pp 61-67.
13. Vizi, E. S., Harsing, L. G., Jr., Horvath, T.: Presynaptic modulation by dopamine of striatal acetylcholine and neurophysal hormone release. In: Neuropeptides and psychosomatic processes, Ed.: Endrőczy, E., Akadémiai Kiadó, Budapest, 1984, pp 347-355.
14. Ronai, A. Z., Serfozo, P., Harsing, L. G., Jr., Vizi, E. S.: The effect of captopril on the presynaptic inhibitory action of met-enkephalin-Arg<sup>6</sup>Phe<sup>7</sup> in isolated organs. In: Regulation of transmitter function: basic and clinical aspects, Eds.: Vizi, E. S., Magyar, K., Akadémiai Kiadó, Budapest, 1984, pp 265-270.
15. Potter, P. E., Harsing, L. G., Jr., Kakucska, I., Gaal, G., Fisher, A., Hanin, I., Vizi, E. S.: In vitro and in vivo effects of AF64A on acetylcholine release. In: Regulation of transmitter function: basic and clinical aspects, Eds.: Vizi, E. S., Magyar, K., Akadémiai Kiadó, Budapest, 1984, pp 283-288.
16. Gaal, G., Potter, P. E., Harsing, L. G., Jr., Kakucska, I., Fisher, A., Hanin, I., Vizi, E. S.: Histological changes caused by AF64A in rat hippocampus. In: Regulation of transmitter function: basic and clinical aspects, Eds.: Vizi, E. S., Magyar, K., Akadémiai Kiadó, Budapest, 1984, pp 295-300.
17. Harsing, L. G., Jr., Magyar, K., Tekes, K., Zsilla, G., Vizi, E. S.: Facilitation by l-deprenyl of nigrostriatal dopaminergic transmission leads to reduced cholinergic activity in the striatum. In: Regulation of transmitter function: basic and clinical aspects, Eds.: Vizi, E. S., Magyar, K., Akadémiai Kiadó, Budapest, 1984, pp 341-344.
18. Harsing, L. G., Jr., Tarczy, M., Bihari, K., Vizi, E. S.: Measurement of plasma l-dopa level by high performance liquid chromatography coupled with electrochemical detection in Parkinsonian patients treated with Madopar. In: Chromatography. The state of the art, Eds.: Kalász, H., Ettre, L. S., Elsevier Amsterdam, 1984, pp 219-224.
19. Harsing, L. G., Jr., Tekes, K., Magyar, K., Vizi, E. S.: In vitro effect of l-deprenyl on dopaminergic and cholinergic neural transmission in caudate nucleus of the rat. In: Chromatography. The state of the art, Eds.: Kalász, H., Ettre, L. S., Elsevier, Amsterdam, 1984, pp 203-218.
20. Zimanyi, I., Somogyi, G. T., Harsing, L. G., Jr., Vizi, E. S.: Release of 3H-noradrenaline by 4-aminopyridine and alpha2-adrenoceptor agonists. In: Pharmacology of Adrenoceptors, Eds.: Szabadi, E., Bradshaw, C. M., Nahorski, S. R., MacMillan Press Ltd., London, 1985, pp 333-334.
21. Potter, P. E., Harsing, L. G. Jr., Gaal, G., Fisher, A., Hanin, I., Vizi, E. S.: Use of HPLC in characterizing the effects of AF64A, a potential cholinergic neurotoxin. In: Symposium on Liquid Chromatography, Eds.: Kalász, H., Ettre, L. S., Elsevier Amsterdam, 1985, pp 225-235.
22. Takats, A., Tarczy, M., Harsing, L., Bihari, K., Csanda, E.: Plasma levodopa level and CSF dopamine/l-dopa ratio in severely disabled parkinsonian patients. In: New Trends in Clinical Neuropharmacology, eds.: Bartko, E. et al., John Libbey and Co. Ltd., 1988, pp 286-288.
23. Somogyi, G. T., Harsing, L. G., Jr., Vizi, E. S.: Central and peripheral effects of CH-38083: a new alpha-2 adrenoceptor antagonist. In: New Concepts in Depression, eds.: Briley, M., Fillion, G., MacMillan Press Ltd., London, 1988, pp. 173-176.
24. Vizi, E. S., Elenkov, I. J., Oberfrank, F., Kiss, J., Harsing, L. G., Jr.: Role of

2004-NOV-30 12:58

HONNAN:EGIS Rt. PARJOG

+36-1-2655763

T-100 0.030/040 F-176

presynaptic alpha-2 heteroreceptors in nonsynaptic modulation of transmitter release. In: International Symposium on Presynaptic Receptors and Neuronal Transporters, Advances in the Biosciences Vol. 82, ed.: Galzin, A. M., Pergamon, Press, Oxford, 1991, pp 297-301.

25. Vizi, E. S., Tarkovacs, G., Doda, M., Harsing, L. G., Jr., Blandizzi, C.: Heterogeneity of alpha-2 adrenoceptors: clinical aspects. In: Trends in Receptor Research, Pharmacology Chemistry Library 18, eds.: Angeli, P., Gulini, U. and Quaglia, W., Elsevier Science Publishers B. V., 1992, pp 115-140.

26. Harsing, L. G., Jr., Bagdy, E., Kiraly, I., Csillik-Perczel, V., Sebestyen, L.: L-Deprenyl desensitizes 5-HT<sub>1B</sub> but not 5-HT<sub>1A</sub> serotonin release-mediating autoreceptors in the raphe nuclei of the rat. Milestones in monoamine oxidase research: discovery of (-)deprenyl. Medicina Publishing House Co, Budapest, 2000, 107-130.

27. Harsing, L. G. Jr., Gígler, G., Albert, M., Szenasi, G., Simo, A., Moricz, K., Varga, A., Ling, I., Bagdy, E., Kiraly, I., Solyom, S., Juranyi, Zs.: Neurotransmitter release in experimental stroke models: the role of glutamate-GABA interaction. In: Frontiers in Clinical Neuroscience: Neurodegeneration and Neuroprotection, eds.: L. Vecsei, Kluwer Publisher, New York, 2004, pp. 21-38.

28. Juranyi, Zs., Harsing, L. G. Jr.: Brain slice chambers designed for in vitro experiments with nervous tissue. Ed: Torok, T. L., In: Monoamine oxidase inhibitors, Medicina, 2004, pp. 281-308.

29. Harsing, L. G., Jr.: Regulation of somatodendritic serotonin release in the midbrain raphe nuclei of the rat, ed.: Mike Ludwig, Kluwer Publisher, New York, 2005, in press.

### 3. CHAPTERS IN HANDBOOKS

1. Harsing László Gábor és Vizi E. Szilveszter: A neurokémia alapjai. Az acetilkolin. Szerkesztette: Magyar Kálmán és Vizi E. Szilveszter, Medicina Budapest, 1987, 166-183.

2. Harsing László és Harsing László Gábor: Élettan-kórélettan gyógyszerészeknek. 2. kiadás. Szerkesztette: Harsing László, Egyetemi tankönyv. Medicina Budapest, 1989, 518-538, 548-573.

3. Harsing László Gábor: A só és vízháztartás gyógyszerterápiája. Gyógyszerterápia. Szerkesztette: Knoll József. Egyetemi tankönyv 7. kiadás. Medicina Budapest, 1991, 397-424.

4. Harsing László Gábor: A só és vízháztartás gyógyszerterápiája. Gyógyszerterápia. Szerkesztette: Knoll József. Egyetemi tankönyv. 8. kiadás. Medicina Budapest, 1993, 397-427.

5. Harsing László Gábor: A só és vízháztartás gyógyszerterápiája. Gyógyszerterápia. Szerkesztette: Knoll József. Egyetemi tankönyv. 9. kiadás. Medicina Budapest, 1995, 397-427.

6. Harsing László Gábor: A só és vízháztartás-vizeletképzés gyógyszerterápiája. Humán farmakológia: a racionális gyógyszerterápia alapjai. Szerkesztette: Vizi E. Szilveszter, Medicina Könyvkiadó, Budapest, 1. kiadás, 1997, 811-847.

7. Harsing László Gábor: A só és vízháztartás-vizeletképzés gyógyszerterápiája. Humán farmakológia: a racionális gyógyszerterápia alapjai. Szerkesztette: Vizi E. Szilveszter, Medicina Könyvkiadó, Budapest, 2. kiadás, 2002, 743-784.

8. Harsing László Gábor: Gyógyszerhatástani. Klinikai gyógyszerterápiák. Szerkesztette:

Dinya Elek, Medicina Könyvkiadó Rt., 2004, in press.

#### 4. ABSTRACTS APPEARED IN JOURNALS

1. Vizi, E. S., Somogyi, G. T., Harsing, L. G., Jr., Zimanyi, I.: Ca<sup>2+</sup>-independent release of noradrenaline. *J. Neurochem.*, 1985, 44, 117.
2. Harsing, L. G., Jr., Somogyi, G. T., Gaal, J., Vizi, E. S.: Pharmacological properties of CH-38083, a selective alpha-2 adrenoceptor antagonist. *Neuroscience Letters*, 1986, 26, 476.
3. Harsing, L. G., Jr., Somogyi, G. T., Vizi, E. S.: Has a physiological role of Ca-independent norepinephrine release in signal transmission? IBRO 2nd World Congr. Neuroscience, 1987, 22, 203.
4. Doda, M. Harsing, L. G., Jr., Vizi, E. S.: Central alpha-2 adrenoceptors and integration of sympathetic outflow in the cat. IBRO 2nd World Congr. Neuroscience, 1987, 22, 1015.
5. Lonart, G., Harsing, L. G., Jr., Vizi, E. S.: A further investigation into the selectivity of CH-38083, a more selective alpha-2 adrenoceptor antagonist than idazoxan in vivo. IBRO 2nd World Congr. Neuroscience, 1987, 22, 218.
6. Gaal, J., Harsing, L. G., Jr., Somogyi, G. T., Szabo, L., Szantay, Cs., Toth, I., Vizi, E. S.: CH-38083, a highly selective alpha-2 adrenoceptor antagonist. Meeting of the British Pharm. Soc., Bart. Br. *J. Pharmacol.*, 1987, 90, 71.
7. Harsing, L. G., Jr., Vizi, E. S.: Selective alpha-2 adrenoceptor antagonists do not affect striatal neurochemical transmission. *Neurochem. Internat.*, 1988, 13, 124.
8. Harsing, L. G., Jr., Bakonyi, A., Csillik, V., Horvath, E., Mate, I., Solyom, S., Szekely, J. I., Yemane, T., Vitalis, B.: The pharmacology of GYKI-46 903, a new memory enhancer. 12th Internat. Congr. Pharm., Montreal, 1994. *Can. J. Physiol. Pharmacol.*, 1994, 72, 13155P.
9. Bagdy E., Horvath E., Sziraki, I., Kiraly, I. and Harsing, L. G.: Further evidence on 5-HT<sub>1A</sub> agonist action of 8-OH-DPAT, in vitro release studies. 17th Annual Meeting of the European Neuroscience Association, Abstr. 51.19, Vienna, 1994. *Eur. J. Neurosci.*, 1994, 7, 51.19.
10. Csillik-Perczel, V., Bakonyi, A., Horvath, E., Solyom, S., Vitalis, B., Yemane, T., Harsing, L. G., Jr.: GYKI-46 903 is a noncompetitive inhibitor of 5-HT<sub>3</sub> receptors. 1st European Congress of Pharmacology, Milan, 1995. *Pharmacol. Research*, 1995, 31, 98.
11. Tapfer, M., Yemane, T., Szekely, J. I., Harsing, L. G., Jr.: Comparison of some alpha-1 and alpha-2 adrenergic blockers in experimental models of prostate hypertrophy. 1st European Congress of Pharmacology, Milan, 1995. *Pharmacol. Research*, 1995, 31, 194.
12. Bagdy, E., Harsing, L. G., Jr.: Opposing role of 5-HT<sub>1A</sub> and 5-HT<sub>3</sub> receptors in the regulation of somatodendritic serotonin release. The German Society of Experimental and Clinical Pharmacology and Toxicology, Vienna, 1997, *Naunyn-Schmiedeberg's Arch. Pharmacol.*, 1997, 356 (4), R54, Abst.
13. Tapfer, M., Yemane, T., Horvath, K., Szekely J. I., Matyus, P., Harsing, L. G., Jr.: GYKI-16 084: a novel mixed postjunctional alpha-1 and alpha-2 adrenoceptor antagonist for the treatment of symptomatic benign prostatic hyperplasia. XIIIth Internat. Cong. Pharmacol., Munchen, 1998, *Naunyn-Schmiedeberg's Arch. Pharmacol.*, 1998, 358 (1), R592, Abst. 6.8.

14. Tapfer, M., Yemane, T., Horvath, K., Szekely J. I., Matyus, P., Harsing, L. G., Jr.: GYKI-16 084: a novel mixed postjunctional alpha-1 and alpha-2 adrenoceptor antagonist for the treatment of symptomatic benign prostatic hyperplasia. *Eur. Urol.*, 1999, 36, 116.
15. Tapfer, M., Csillik-Perczel, V., Horvath, K., Matyus, P., Harsing, L. G., Jr.: Effect of GYKI-16 084 on micturition disorders in benign prostatic hyperplasia and spinal cord injury models. 2nd European Congress of Pharmacology, 1999, Budapest, Fundamental and Clinical Pharmacology, 1999, 13, Suppl. 1., PM173.
16. Vitalis, B., Csillik-Perczel, V., Sebestyen, L., Mate, G., Solyom, S., Harsing, L. G., Jr.: Noncompetitive-type interaction of GYKI-46 903 with 5-HT<sub>3</sub> receptors. Joint Meeting of the ISN and the ESN, 1999, Berlin. *J. Neurochem.*, 1999, 73, S146C.
17. Harsing, L. G., Jr., Kiraly, I., Bagdy, E.: Signal transduction pathways coupled to serotonin release-inhibitory 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> receptors in rat raphe nuclei slices. *J. Physiol., Proceedings*, 2000, 526, 67P.
18. Kapus, G., Kertesz, Sz., Vegh, M., Harsing, L. G., Jr., Levay, G.: Interaction of AMPA receptor modulators in the chicken retina. Meeting of the British Pharm. Soc., Bristol, Br. *J. Pharmacol.*, 2002, 135, 87P.
19. Levay, G., Sziray, N., Haller, J., Simig, G., Danyi, D., Szenasi, G., Harsing, L. G., Gacsalyi, I.: EGIS-8858: Preclinical evaluation of a new anxiolytic/antistress compound with no sedative side effects. XIVth World Congress of Pharmacology, San Francisco, CA, 2002, 32.13. *Pharmacologist* 2002, 44, 32.13.
20. Juranyi, Zs., Harsing, L. G., Jr., Zigmond, M. J. [<sup>3</sup>H]Dopamine release in rat striatum after electrical stimulation of cortex in vitro. The use of cortex-striatum slices. Meeting of the British Pharm. Soc., Glasgow, Br. *J. Pharmacol.*, 2002, 137, 128P.
21. Szabo, G., Egyed, A., Harsing, L. G., Jr.: A new and simple method for measuring neurotransmitters. The GlyT1 transporter. Special FEBS Meeting. Meeting on Signal transduction, Brussels, 2003, Abst. 1009 (PW18). *Eur. J. Biochem.*, 2003, 270, PS01-1009.
22. Szenasi, G., Gigler, G., Gacsalyi, I., Simo, A., Moricz, K., Sziray, N., Albert, M., Szabo, G., Schmidt, E., Egyed, A., Levay, G., Harsing, L. G., Jr.: Beneficial and detrimental effects of Org 24461 and NFPS, two glycine transporter-1 inhibitors in rats and mice. 6th IBRO World Congress of Neuroscience, Prague, 2003, Abstr. 3189. *Neuroscience*, 2003, 119, 3189.
23. Moricz, K., Matucz, E., Gigler, G., Simo, A., Harsing, L. G., Szenasi, G.: Effects of EGIS-8332 in focal ischemia models in rats. MIT Vándorgyűlés, Balatonfüred, 2003. *Clinical Neuroscience*, 2003, 56, 60.
24. Sziray, N., Levay, G., Haller, J., Simig, Gy., Danyi, D., Szenasi, G., Harsing, L. G., Gacsalyi, I.: EGIS-8858: Preclinical pharmacology of a new anxiolytic/antostress compound with no sedative side effects. MIT Vándorgyűlés, Balatonfüred, 2003. *Clinical Neuroscience*, 2003, 56, 87.
25. Gyonos, I., Gacsalyi, I., Harsing, L. G., Jr., Levay, Gy.: Examination of various benzodiazepines in the Morris water maze. MIT Vándorgyűlés, Balatonfüred, 2003. *Clinical Neuroscience*, 2003, 56, 31.
26. Harsing, L. G., Jr., Juranyi, Zs.: Evidence for a reciprocal serotonergic-glutamatergic interaction in the raphe nuclei: involvement of 5-HT<sub>7</sub> receptors. *Proc. Austr. Neurosci. Soc.* 2004, 15, 78. 24th Annual Meeting of the Australian Neuroscience Society, Melbourne, 2004, Abstr. 120.

## 5. ABTRACTS PUBLISHED

1. Harsing, L. G., Jr., Friedmann, T. Magyar, K., Knoll, J.: The effect of azidoethylmorphine and related substances on cough and respiration. 2nd Congr. Hung. Pharm. Soc., Budapest, 1974.
2. Harsing, L. G., Jr., Friedmann, T. Magyar, K., Knoll, J.: The effect of azidoethylmorphine and related substances on cough and respiration. Joint Meeting of the German, Hung., Portuguese and Yugoslav Pharma. Soc., Graz, 1974.
3. Hársing, L. G., Jr., Friedmann, T. Magyar, K., Knoll, J.: Különböző támadáspontú köhögéscsillapítók potencirozhatósága probonnal. MÉT 40. Vándorgyűlés, Debrecen, 1974.
4. Harsing, L. G., Jr., Friedmann, T. Magyar, K., Knoll, J.: Az azidomorfin köhögéscsillapító hatásának farmakológiai vizsgálata. MÉT 41. Vándorgyűlés, Szeged 1975.
5. Hársing, L. G., Jr., Friedmann, T. Magyar, K., Knoll, J.: The antitussive effect of azidomorphines. 6th Internat. Congr. Pharm., Helsinki, 1975.
6. Friedmann, T., Hársing, L. G., Jr., Knoll, J.: Az azidomorfin származékok légzésre gyakorolt hatásainak vizsgálata, MÉT 41. Vándorgyűlés, Szeged, 1975.
7. Friedmann, T., Harsing, L. G., Jr., Knoll, J.: Kinetic studies on respiration and antitussive effects of azidomorphine. 5th Congr. Pol. Pharm. Soc., Szczecin, 1975.
8. Harsing, L. G., Jr., Friedmann, T. Magyar, K., Knoll, J.: On the mechanism of the synergism between homopirimidazol and azidomorphine derivatives. 6th Yugoslavian Pharm. Meeting, Ljubljana, 1976.
9. Harsing, L. G., Jr., Friedmann, T. Magyar, K., Knoll, J.: Synergism of rymazolium and various antitussive agents. MÉT 42. Vándorgyűlés Budapest, 1976.
10. Friedmann, T., Harsing, L. G., Jr., Knoll, J.: The involvement of opiate B receptors in the antitussive effects of azidomorphine. Pharm. Meeting, Ljubljana, 1976.
11. Friedmann, T., Hársing, L. G., Jr., Somogyi, G. T., Knoll, J.: Azidomorfin származékok izolált szerven és egész állaton mért hatékonyságának összehasonlítása. MÉT 42. Vándorgyűlés Budapest, 1976.
12. Friedmann, T., Harsing, L. G., Jr., Knoll, J.: The antitussive effects of azidomorphine and 14-hydroxy-azidomorphine. 2nd Congr. Hung. Pharm. Soc., Budapest, 1976.
13. Harsing, L. G., Jr., Illes, P., Vizi, E. S., Knoll, J.: The inhibitory effect of PGE1 on acetylcholine relese in he cat brain. 28th Internat. Congr. Physiol. Sci., Paris, 1977.
14. Harsing, L. G., Jr., Vizi, E. S., Knoll, J.: Increase by endorphins of acetylcholine release from isolated striatal slices of the rat. 6th Congr. of the Pol. Pharm. Soc., Kattowice, 1977.
15. Vizi, E. S., Ronai, A. Z., Harsing, L. G., Jr., Knoll, J.: Presynaptic inhibition by dopamine of acetylcholine release from isolated striatum of the rat. 28th Internat. Congr. of Physiol. Sci., Paris, 1977.
16. Harsing, L. G., Knoll, J.: Inhibition of dopamine uptake in the rat striatum as a possible mechanism of action of (-)-deprenyl in Parkinson's disease. 7th Internat. Congr. Pharm., Paris, 1978.
17. Harsing, L. G., Knoll, J., Vizi, E. S.: Az extrapyramidális rendszer neurokémiai transzmissziójának szabályozása. XLIV. MÉT Vándorgyűlés, 1978.
18. Harsing, L. G., Jr., Vizi, E. S.: Different sensitivity of pre- and postsynaptic dopamine receptors in the rat striatum. 3rd Congr. Hung. Pharm. Soc., Budapest, 1979.
19. Harsing, L. G., Jr., Tekes, K., Magyar, K., Vizi, E. S., Knoll, J.: Deprenyl inhibits

dopamine uptake in the rat striatum in vivo. 3rd Congr. Hung. Pharm. Soc., Budapest, 1979.

20. Harsing, L. G., Jr., Vizi, E. S.: Sensitivity of opiate receptors in withdrawal syndrome. In: Aminergic and peptidergic receptors. Symposium for Aminergic and Peptidergic Receptors, Szeged, 1979.

21. Vizi, E. S., Harsing, L. G., Jr.: Difference in sensitivity of opiate receptors in the striatum to beta-endorphin and enkephalins: evidence that catalepsy is related to enhanced acetylcholine release from cholinergic interneurons. Symposium for Aminergic and Peptidergic Receptors, Szeged, 1979.

22. Harsing, L. G., Jr., Yang, H.-Y. T., Costa, E.: GABAergic modulation of endorphinergic neurotransmission in striatal slices of the rat. FASEB 65th Annual Meeting, Atlanta, GA, 1981.

23. Harsing, L. G., Jr., Yang, H.-Y. T., Govoni, S., Costa, E.: Modification of opioid peptide level in the hypothalamus by chronic treatment with d-fenfluramine. 11th Annual Meeting of Soc. for Neuroscience, Los Angeles, CA, 1981.

24. Harsing, L. G. Jr., Vizi, E. S.: Characterization of the release of dopamine and DOPAC from striatal slices of the rat. Chromatographic Meeting, Budapest, 1983.

25. Harsing, L. G., Jr., Vizi, E. S.: Dopamine felszabadulás mérés patkány striátum szeletből intenzív folyadék kromatografia-elektrokémiai detekció (HPLC-ED) módszerrel. MÉT 48. Vándorgyűlés 1983.

26. Harsing, L. G., Jr., Magyar, K., Tekes, K., Zsilla, G., Vizi, E. S.: Facilitation by l-deprenyl of nigrostriatal dopaminergic transmission leads to reduced cholinergic activity in the striatum. 5th ESN Meeting, Budapest, 1984.

27. Potter, P. A., Harsing, L. G., Jr., Hanin, I., Vizi, E. S.: Use of HPLC in characterizing the effects of AF64A, a potential cholinergic neurotoxin. Symposium on Liquid Chromatography, Budapest, 1984.

28. Potter, P. E., Harsing, L. G., Jr., Kakucska, I., Gaal, G., Fisher, A., Hanin, I., Vizi, E. S.: In vitro and in vivo effects of AF64A on acetylcholine release. 5th ESN Meeting, Budapest, 1984.

29. Gaal, G., Potter, P. E., Harsing, L. G., Jr., Kakucska, I., Fisher, A., Hanin, I., Vizi, E. S.: Histological changes caused by AF64A in rat hippocampus. 5th ESN Meeting, Budapest, 1984.

30. Zimanyi, I., Somogyi, G. T., Harsing, L. G., Jr., Vizi, E. S.: Release of 3H-noradrenaline by 4-aminopyridine and alpha2-adrenoceptor agonists. 9th Internat. Congr. Pharm., London, 1984.

31. Harsing, L. G., Jr., Somogyi, G. T., Gaal, J., Vizi, E. S.: Pharmacological properties of CH-38083, a selective alpha-2 adrenoceptor antagonist. 10th Eur. Neurosci. Congr., Marseille, 1986.

32. Harsing, L. G., Jr., Somogyi, G. T., Toth, I., Vizi, E. S.: On the selectivity of CH-38083, a new alpha-2 adrenoceptor antagonist. 10th Internat. Congr. Pharm., Sydney, 1987.

33. Harsing, L. G., Jr., Vizi, E. S.: Excitatory amino acids (glutamate and aspartate) in the rat brain: measurement with liquid chromatography coupled with electrochemical detection. 1st Joint Meeting of the Hung. and Italian Pharm. Societies, Verona, 1988.

34. Somogyi, G. T., Harsing, L. G., Jr., Vizi, E. S.: Central and peripheral effects of CH-38083: a new alpha-2 adrenoceptor antagonist. Symposium on New Concepts in



Depression, Castres, 1988.

35. Lonart, G. Harsing, L. G., Jr., Vizi, E. S.: Pharmacological evidence for two types of presynaptic alpha-2 adrenoceptors. 1st Joint Meeting of the Hung. and Italian Pharm. Soc., Verona, 1988.

36. Vizi, E. S., Kapocsi, J., Harsing, L. G., Jr., Del Tacca, M.: Heterogeneity of presynaptic alpha-2 adrenoceptors. 2nd Joint Meeting of the Hung. and Italian Pharm. Soc., Budapest, 1990.

37. Gyamati, S., Harsing, L. G., Jr., Tekes, K., Knoll, J.: Repeated administration of (-)-deprenyl leaves the mesolimbic dopaminergic activity unchanged. 2nd Joint Meeting of the Hung. and Italian Pharm. Soc., Budapest, 1990.

38. Harsing, L. G., Jr., Sershen, H., Vizi, E. S., Lajtha, A.: [<sup>3</sup>H]Dopamine release from nicotine pretreated mouse striatum. 21st Annual Meeting of the American Soc. for Neurochemistry, Phoenix, AZ, 335, 1990.

39. Sershen, H., Harsing, L., Toth, E., Lajtha, A.: Acetyl-L-carnitine and dopaminergic responses. ESN Meeting, Leipzig, 1990.

40. Harsing, L. G., Jr., Sershen, H., Lajtha, A.: Autoreceptors mediating synthesis and release of dopamine in nicotine-pretreated mouse striatum. 22nd Annual Meeting of the American Soc. for Neurochemistry, Charleston, SC, 1991.

41. Lajtha, A., Hashim, A., Harsing, L., Sershen H.: Behavioral effects of autoreceptor desensitization by chronic nicotine. 22nd Annual Meeting of the American Soc. for Neurochemistry, Charleston, SC, 1991.

42. Harsing, L. G., Jr., Sershen, H., Lajtha, A.: Dopamine autoreceptor desensitization by chronic nicotine in mouse striatum. Naturally Occurring Compounds That Affect Neurotransmission, Internat. Foundation of Science Workshop, Buenos Aires-Montevideo, 1991.

43. Harsing, L. G., Jr., Sershen, H., Lajtha, A.: Evidence that ibugaine releases dopamine from the cytoplasmic pool in isolated mouse striatum. 23rd Annual Meeting of the American Soc. for Neurochemistry, Houston, TX, 1992.

44. Bakonyi, A., Zempleni, E., Vitalis, B., Harsing, L.: GYKI-46 903, a new CNS-active 5-HT<sub>3</sub> receptor ligand. 2nd IUBMB Conference Biochemistry and Cell Membranes, Bari 1993.

45. Harsing, L. G., Bagdy, E., Sziraki, I., Kiraly, I. and Horvath, E. J.: Direct evidence that somatodendritic 5-HT<sub>1A</sub>-receptors in the raphe nuclei are coupled to potassium channels. The 3rd International Conference on Central Nervous System Slice Preparations, Abstr. 57, Louisville, KY, 1994.

46. Horvath, E. J., Palkovits, M., Fekete, M. I. K. and Harsing, L.: Autoradiographic localization and quantitative determination of novel specific binding sites of axiolytic homophthalazines: effect of the binding sites on CNS. 16th International Congress of Biochemistry and Molecular Biology, P10-59, New Delhi, 1994.

47. Bakonyi, A., Horvath, E., Solyom, S. and Harsing, L.: Comparative biochemical studies with new azabicyclo compounds acting on 5-HT<sub>3</sub> and 5-HT<sub>4</sub> receptors. 16th International Congress of Biochemistry and Molecular Biology, P10-18, New Delhi, 1994.

48. Vitalis, B., Bakonyi, A., Csillik-Perczel, V., Ronai, A., Yemane, T., Horvath, E., Horvath, K., Szekely, J. I., Harsing, L. G., Jr.: Characterization of the interaction of GYKI-46 903 with 5-HT<sub>3</sub> and muscarinic receptors. 10th Camerino-Noordwijkerhout Symposium, 1995, Abstract P14.

49. Harsing, L. G., Jr., Zigmond, M. J.: Dopamine exerts both synaptic and nonsynaptic influences on GABAergic neurons in the neostriatum. 25th Annual Meeting, Society for Neuroscience, San Diego, CA, 1995, Abst. 541.16.
50. Harsing, L. G., Jr., Zigmond, M. J.: Short term and long term effects of 6-hydroxydopamine on dopaminergic inhibition of GABA release in neostriatum. 26th Annual Meeting, Society for Neuroscience, Washington, D. C., 1996, Abst. 39.8.
51. Tapfer, M., Yemane, T., Horvath, K., Szekely, J. I., Harsing, L. G. Jr., Varga, I., Zara-Kaczian, E., Behr, A., Matyus, P.: GYKI-16084, a novel drug candidate for the symptomatic treatment of benign prostatic hyperplasia. 5th International Symposium on the Chemistry and Pharmacology of Pyridazines, Sopron, 1996.
52. Harsing, L. G., Jr. Zigmond, M. J.: Cholinergic and dopaminergic interactions in the regulation of GABA release in neostriatum. 3rd SONA Interantional Neuroscience Conference and 2nd IBRO Regional Congress, Cape Town, 1997, Abstr. 53.
53. Harsing, L. G., Jr., Bagdy, E.: Feedback stimulation of somatodendritic serotonin release: opposing role of 5-HT<sub>1A</sub> and 5-HT<sub>3</sub> receptors. 27th Annual Meeting, Society for Neuroscience, New Orleans, LA, 1997, Abst. 907.11.
54. Vitalis, B., Csillik-Perczel, V., Barlocco, D., Szekely, J. I., Matyus, P., Harsing, L. G.: Antimuscarinic profile of a condensed pyridazine derivative. 1st Italian-Swiss Meeting on Medicinal Chemistry, Torino, 1997, Abst.
55. Harsing, L. G., Jr., Somogyi, P., Hamori, T., Solyom, S.: Glutamate-GABA interaction in neostriatum: the role of AMPA receptors in the regulation of [<sup>3</sup>H]GABA release. 28th Annual Meeting, Society for Neuroscience, Los Angeles, CA, 1998, Abst. 824.19.
56. Matyus, P., Varga, I., Tapfer, M., Harsing, L., Tomory, E., Simay, A.: GYKI 16 084: a new drug candidate for treatment of benign prostate hyperplasia. XVth EFMC International Symposium on Medicinal Chemistry, Edingburgh, 1998, p.4.
57. Hajos, M., Sharp, T., E. Bagdy, Harsing, L. G., Jr.: Functional significance of burst firing in 5-HT neuronal activity: effects on 5-HT release and postsynaptic response. British Neuroscience Association, 15th National Meeting, Liverpool, 1999.
58. Harsing, L. G., Jr., Kiraly, I., Bagdy: Reciprocal innervation between serotonergic and GABAergic neurons in raphe nuclei of the rat. 29th Annual Meeting, Society for Neuroscience, Miami Beach, FL, 1999, Abst. 481.9.
59. Csillik-Perczel, V., Tapfer, M. K., Matyus, P., Harsing, L. G., Jr.: The effects of GYKI-16 084, a novel mixed postjunctional alpha<sub>1</sub>- and alpha<sub>2</sub>-adrenoceptor antagonist on micturition dysfunction induced by spinal cord injury in rat. Autonomic neuroscience: basic and Clinical. Int. Soc. Auton. Neurosci. Millenium Congress, London, 2000, Abstr.
60. Harsing, L. G., Jr., Kiraly, I., Bagdy: Contribution of phosphoinositide pathway to 5-HT<sub>1A/1B</sub> receptor-mediated serotonin release inhibition in the raphe nuclei of the rat. 30th Annual Meeting, Society for Neuroscience, New Orleans, LA, 2000, Abst. 145.7.
61. Harsing, L. G., Jr., Salamon, C., Bagdy, E.: The role of glycine<sub>B</sub> binding site in the regulation of NMDA-mediated [<sup>3</sup>H]GABA release in rat striatal slices. 5th SONA Interantional Neuroscience Conference, Nairobi, Kenya, 2001.
62. Leveleki, C., Kompagne H., Gacsalyi, I., Barkoczy, J., Schmidt, E., Pallagi, K., Harsing, L. G., Jr., Levay, G.: Anxiolytic properties of the new atypical antipsychotic compounds synthesized at EGIS. CINP Hungarian Regional Congress, Budapest, 2001.

2004-NOV-30 13:00

HONNAN:EGIS R. PARJOG

+36-1-2655763

T-109 0.046/049 F-176

63. Harsing, L. G., Jr., Pallagi, K., Egyed, A.: 5-HT<sub>7</sub> receptors regulate serotonin release in raphe nuclei. 31th Annual Meeting, Society for Neuroscience, San Diego, CA, 2001, Abst. 380.1.
64. Gacsalyi, I., Schmidt, E., Bozsing, D., Harsing, L. G., Levay, G.: EGIS-10730 is a possible alternative to benzodiazepine therapy in anxiety disorders. FENS Forum, Paris, 2002.
65. Hársing, L. G.: Ionotróp glutamáterg mechanizmusok a központi idegrendszerben: NMDA-glicin kölcsönhatások. Farmako-kinetikai és Gyógyszermetabolizmus Szimpózium, Mátraháza, 2002.
66. Szenasi, G., Hegedus, M., Wellmann, J., Harsing, L. G., Rochat, C., Kovacs, A.: Testing of new chemical entities in rabbits in vitro and in vivo for prediction of cardiac action potential prolongation in human. ISP Congress Budapest, 2002.
67. Harsing, L. G., Jr., Gacsalyi, I., Gigler, G., Szabo, G.: Effects of the glycine transporter (GlyT1) inhibitor Org 24461 and NFPS on [<sup>3</sup>H]glycine release in rat hippocampal slices. 32nd Annual Meeting, Society for Neuroscience, Orlando, FL, 2002, Abst.
68. Levay, G., Harsing, L. G., Jr., Gacsalyi, I., Egyed, A., Barkoczy, J., Simig, J., Bourin, M., Sebban, C., Spedding, M.: Novel anxiolytics with unknown mechanism of action. 32nd Annual Meeting, Society for Neuroscience, Orlando, FL, 2002, Abst.
70. Harsing, L. G., Jr., Gigler, G., Juranyi, Zs., Szenasi, G.: Neurotransmitter release in experimental stroke models: the role of glutamate. Eur. Soc. Clin. Neuropharm. (ESCNP) Conference, 2002,
71. Kertesz, S., Kapus, G., Vegh, M., Szucs, Z., Kovacs, G., Harsing, L. G., Levay, G.: Az S18986 AMPA receptor pozitív modulátor hatásának összehasonlító vizsgálata in vitro. MKKFT V. Kongresszusa, 2002.
72. Kapus, G., Kertész, S., Lévy, G., Hársing, L. G., Spedding, M.: Az antidepresszáns tianeptine Ca<sup>2+</sup>-függően potenciozza a szinaptikus aktivitást a hippocampusban. MKKFT V. Kongresszusa, 2002.
73. Haraszti, H., Levekei, Cs., Gacsalyi, I., Hársing, L. G., Lévy, G.: Maternális depriváció hatása felnőtt patkányok viselkedésére szorongást keltő helyzetben. MKKFT V. Kongresszusa, 2002.
74. Gigler, G., Simó, A., Móricz, K., Barkóczy, J., Szénási G., Hársing, L. G., Lévy, G.: EGIS-8332: egy nem-kompetitív AMPA antagonistá hatása agyi iszkémiában. MKKFT V. Kongresszusa, 2002.
75. Móricz, K., Matucz, E., Gigler, G., Simó, A., Hársing, L. G., Szénási. G.: Az EGIS-8332 vizsgálata tranziens fokális agyi iszkémiában patkányon. MKKFT V. Kongresszusa, 2002.
76. Juranyi, Zs., Hársing, L. G., Zigmond, M.: Új metodika az agykéreg striatumra gyakorolt hatásának vizsgálatára komplex corticostriatalis agyszeletben radioaktív release technikával. MKKFT V. Kongresszusa, 2002.
77. Bagdy, E., Harsing, L. G., Jr., Kiraly, I., Andrási, F.: The role of glutamate-GABA interaction in ex vivo and in vitro experimental stroke models in rats. Monitoring Molecules in Neuroscience, 10th International Conference on In vivo methods, Stockholm, 2003.
78. Gressens, P., Spedding, M., Villa, P., Medja, F., Williamson, T., Gigler, G., Kertesz S., Kapus, G., Levay, G., Szenasi, G., Barkoczy, J., Harsing, L. G., Jr.: The effects

of novel AMPA antagonists in models of neurodegeneration of stroke and neurodegeneration. 33rd Annual Meeting, Society for Neuroscience, New Orleans, La, 2003, Abst.

79. Harsing, L. G., Jr., Juranyi, Zs., Zigmond, M. J.: Cortical stimulation influences striatal dopamine release via GABAergic neurons in corticostriatal slices of the rat. 33rd Annual Meeting, Society for Neuroscience, New Orleans, La, 2003, Abst. 705.8

80. Levay, Gy. Harsing, L. G., Jr.,  
33rd Annual Meeting, Society for Neuroscience, New Orleans, La, 2003, Abst.

81. Gigler, G., Simó, A., Móricz, K., Kapus, G., Végh, M., Kertész, Sz., Lévy, Gy., Harsing, L. G., Szénási, G.: Egy nem-kompetitív AMPA antagonistá vegyület, az EGIS-9637 neuroprotektív hatása. MÉT Vándorgyűlés, Pécs, 2003.

82. Móricz, K., Matucz, É., Gigler, G., Simó, A., Harsing, L. G., Szénási G.: Neuroprotektív tranzienst fokális agyi ischémiában. MÉT Vándorgyűlés, Pécs, 2003.

83. Simó, A., Gigler, G., Móricz, K., Szénási, G., Lévy, Gy., Harsing, L. G.: Az AMPA receptor antagonisták hatása patkány globális ischémiában. MÉT Vándorgyűlés, Pécs, 2003.

84. Bagdy, E., Harsing, L. G., Jr., Kiraly, I. and Andrási, F.: The role of glutamate-GABA interaction in ex vivo and in vitro experimntal stroke models in rats. Monitoring Molecules in Neuroscience, Proceedings of the 10th International Conference on In Vivo Methods, Stockholm, 2003, pp. 244-245.

85. Csílik-Perczel, V., Harsing, LG, Jr.: The role of alpha2 adrenoceptor subtypes in the regulation of micturition reflex in rats. Scandinavian Cong. Physiol. Pharmacol., Odense, Denmark, 2003.

86. Harsing, L. G., Jr., Juranyi, Zs.: Evidence for a reciprocal serotonergic-glutamatergic interaction in the raphe nuclei: involvement of 5-HT<sub>7</sub> receptors. 24th Annual Meeting, Australian Neuroscience Society, Melbourne, 2004, Abstr. 120.

87. Kertész, S., Kapus, G., Vegh, M., Szucs, Zs., Kovacs, G., Harsing, L. G., Levay, G.: The AMPA potentiator benzothiazide S 18986, cyclothiazide and IDRA-21: a comperative in vitro study. IBRO Workshop, Budapest 2004.

88. Juranyi, Zs., Marko, B., Harsing, L. G., Jr.: Depletion of GABA decreased the evoked [<sup>3</sup>H]dopamine release in striatum in the presence of NMDA receptor blockade in corticostriatal slices. IBRO Workshop, Budapest 2004.

89. Vegh, M., Kapus, G., Kertész, Sz., Kovacs, G., Barkoczy, J., Szabo, G., Harsing, L., Levay, G.: 3-Methyl substitution of the 4-aminophenyl moiety and 8-halogenation separately increase alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate channel blocking ability of 1-(4-aminophenyl)-2,3-benzodiazepine compounds. FENS, 2004, Porto

90. Konpagné H., Leveleki, Cs., Gacsalyi, I., Harsing, L. G., Levay Gy.: Behavioural analysis of two animal models of depression. FENS, Porto, 2004, P. 128

91. Gigler, G., Moricz, K., Albert, M., Matucz, E., Agoston, M., Simo, A., Benedek, A., Barkoczy, J., Harsing, L. G., Szenasi, G.: Neuroprotective efficacy of EGIS-8332, a non-competitive AMPA antagonist, in transient focal cerebral ischemia and multiple sclerosis test in rats. Spring Neuropathology Conference, Budapest, 2004.

92. Gigler, G., Simo, A., Moricz, K., Agoston, M., Vegh, M., Kapus, G., Kertész, Sz., Levay, Gy., Harsing, L. G., Szenasi, G.: Neuroprotective efficacy of EGIS-8332, a non-competitive AMPA antagonist in transient focal cerebral ischemia and multiple sclerosis test

2004-NOV-30 13:01 HONNAN:EGIS RL:IPARJOG

+36-1-2655763

T-100 0.048/048 F-176

in rats. IUPHAR XXth Internat. Cong. Pharmacol., Porto, 2004.

93. Moricz, K., Gigler, G., Albert, M., Matucz, E., Agoston, M., Simo, A., Benedek, A., Barkoczy, J., Harsing, L. G., Levay, G., Szenasi, G.: Effect of EGIS-8332, a non-competitive AMPA antagonist, in animal models of transient focal ischemia and multiple sclerosis. 7th Internat Cong. Neuroimmunology, Venice, 2004, Abstr.

94. Megyeri, K., Marko, B., Sziray, N., Levay, G., Harsing, L. G., Jr.: Blockade of striatal AMPA receptors leads to levodopa spearing in dopamine-deficient basal ganglia of the rat. 34th Annual Meeting, Society for Neuroscience, San Diego, 2004, Abstr.

95. Juranyi, Z., Harsing, L. G., Jr.: Temperature-dependent [ $^3\text{H}$ ]glycine release in response to electrical stimulation and exogenous glycine in the presence of Org-24461, a glycine transporter1 inhibitor in rat hippocampal slices. 34th Annual Meeting, Society for Neuroscience, San Diego, 2004, Abstr.

## 6. INVITED LECTURES

1. Dr. E. Costa, Laboratory of Preclinical Pharmacology, National Institute of Mental Health: Conversion of Arg6-Phe7-Met5-enkephalin to Met5-enkephalin in isolated organs.

87. Csillik-Perczel, V., Harsing LG, Jr.: The role of alpha2 adrenoceptor subtypes in the regulation of micturition reflex in the rat Washington, D. C., 1982.

2. Measurement of acetylcholine release from brain slices. Technique of Bioassay. Pjõng Yang-i Orvostudományi Egyetem, Pjõng Yang, 1984.

3. Dr. J.-P. Schwartz, Department of Pharmacology, University of Geneva, Medical School. Alpha-2 autoreceptors, alpha-2 antagonists and noradrenergic neurotransmission. Geneva, 1987.

4. Dr. H. A. Campos, Universidad Central de Venezuela Fac. de Medocona, Caracas: The pharmacology of berbanes, a new group of alpha-2 adrenoceptor antagonists. Caracas, 1988.

5. Dr. Abel Lajtha, Center for Neurochemistry, Nathan Kline Institute for Psychiatric Resesarch, Orangeburg, NY, USA: Neurotransmitter pools in dopaminergic nerve terminals and their role in actions of drugs. Orangeburg, NY, 1993.

6. A Magyar Farmakológiai Társaság Experimentális Farmakológiai Szekció rendezésében: Neuronális transmitter raktárak, gyógyszerekkel történő befolyásolhatóság. Magyar Tudományos Akadémia, Kísérleti Orvostudományi Kutató Intézet, Budapest, 1993.

7. Dr. M. J. Zigmond, Department of Neuroscience, University of Pittsburgh: The use of complex brain slices in investigating basal ganglia neurotransmission. Pittsburgh, PA 1995.

8. Harsing, L. G.: Új eredmények az  $\alpha$  adrenerg receptorok kutatásában, Budapest, 1999.

9. Harsing, L. G., Jr.: Regulation of 5-HT release from raphe nuclei by different 5-HT receptors. CINP Hungarian Regional Congress, Budapest, 2001.

10. Harsing, L. G., Jr., Gacsalyi, I., Levay, G., Schmidt, E., Matyus, P., Sebban, C., Spedding, M.: Some pharmacological effects of glycine transporter (GlyT1) inhibitors. 35th Annual Winter Conference of Brain Research, Snowmass Village, CO, 2002.

11. Harsing, L. G.: Az extrapiramidális rendszer neurokémiai transzmissziója. Issekutz Béla Emlékelőadás, Budapest, 2002.

12. Harsing, L. G., Jr., Gigler, G., Juranyi, Zs., Szenasi, G.: Neurotransmitter release in experimental stroke models: the role of glutamate. Frontiers in Clinical Neuroscience,

2004-NOV-30 13:01 HONNAN:EGIS Rt. PARJOG

+36-1-2655763

T-109 0.049/049 F-176

Budapest, 2002.

13. Hársing, L. G.: A glicin transzporter gátlók neurobiológiája, farmakológiája és lehetséges terápiás alkalmazásai. MBKE Gyógyszerbiokémiai Szakosztály, Balatonőszöd, 2004.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**